Compounding information collection submitted to the budget office for review

The agency recorded that the 503A and 503B human drug compounding information collection has gone to the Office of Management and Budget for review and clearance.

Washington, 23 February 2026 — The Food and Drug Administration announced that a proposed collection of information covering human drug compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act has been submitted to the Office of Management and Budget for review and clearance under the Paperwork Reduction Act of 1995.

Source documents

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act Notice · Food and Drug Administration · 23 February 2026
Identifier
Federal Register document 2026-03448
As the record states
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Document number
2026-03448